Rhythm Pharmaceuticals (NASDAQ: RYTM) Reported on the August 4 Q2 2026 Earnings Call That the US Launch of IMCIVREE (Setmelanotide, an Alpha-Melanocyte-Stimulating Hormone (Alpha-MSH) Analog Peptide That Activates Melanocortin-4 Receptor for Appetite Suppression) in the Newly-Approved Acquired Hypothalamic Obesity Indication Has Recorded More Than 400 Patient Start Forms Since FDA Approval in Late June 2026; The Launch Ranks Among the Stronger Rare-Disease Peptide Launches of the Year to Date and Extends the Melanocortin-Agonist Franchise Beyond the Original Rare Genetic Obesity Syndromes (POMC, LEPR, PCSK1 Deficiency) That IMCIVREE Was Initially Approved For; The Acquired Hypothalamic Obesity Indication Addresses Patients With Hypothalamic Damage From Brain Tumors, Radiation, or Trauma That Disrupts Normal Melanocortin Signaling and Leads to Severe Obesity
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported on the August 4, 2026 Q2 2026 earnings call that the US launch of IMCIVREE (setmelanotide) in the newly-approved acquired hypothalamic obesity indication has recorded more than 400 patient start forms since FDA approval in late June 2026. Setmelanotide is a synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analog peptide that activates the melanocortin-4 receptor (MC4R) to produce appetite suppression; the peptide is administered as a daily subcutaneous injection. The launch ranks among the stronger rare-disease peptide launches of the year to date and extends the melanocortin-agonist franchise beyond the original rare genetic obesity syndromes (POMC, LEPR, PCSK1 deficiency) that IMCIVREE was initially approved for in 2020. The acquired hypothalamic obesity indication addresses patients with hypothalamic damage from brain tumors (particularly craniopharyngioma), radiation therapy, surgery, or trauma that disrupts normal melanocortin signaling and leads to severe obesity with dysfunctional appetite regulation. The therapeutic story is mechanistically adjacent to but distinct from the alpha-MSH gray-market use of melanotan II (which activates the same broader melanocortin receptor family for tanning and appetite suppression); setmelanotide has substantially more selectivity for MC4R specifically, an established safety monitoring program, and full FDA approval under the rare-disease pathway. IMCIVREE full-year 2026 revenue guidance is expected to reflect the acquired hypothalamic obesity launch trajectory.